Loading BSD 13F portfolios...
Elite Manager Tracking
The Top 150 BSDs
Real-time 13F holding analysis for the industry's most influential institutional investors. Track conviction shifts, new entries, and structural exits.
Mark Bussard
✓ VerifiedInstitutional Investor • Rock Springs Capital
Value
$1.9B
Stocks
47 Stocks (1 new)
Turnover
3.0%
Top Holdings
RVMD(11.94%) TVTX(7.14%) LLY(6.83%) MDGL(5.42%) MIRM(5.39%)
About Investor
Established investor leading Rock Springs Capital, with expertise in healthcare and biotechnology sector expertise. Has built a strong track record by focusing on fundamental research and maintaining a consistent investment approach through various market environments.
Investor Philosophy
Investment philosophy details pending verification.
Mark Bussard Top Holdings
| Ticker | P/C | Company Name | Sector | Market Value | Shares | Weight | Chg Shares | % Chg |
|---|---|---|---|---|---|---|---|---|
| RVMD | None | Revolution Medicines, Inc. | Healthcare | $207.0M | 0 | 11.9% | 0 | No Change |
| TVTX | None | Travere Therapeutics, Inc. | Health Care | $123.8M | 0 | 7.1% | 0 | No Change |
| LLY | None | Eli Lilly & Co. | Health Care | $118.4M | 0 | 6.8% | 0 | No Change |
| MDGL | None | Madrigal Pharmaceuticals, Inc. | Health Care | $94.0M | 0 | 5.4% | 0 | No Change |
| MIRM | None | Mirum Pharmaceuticals, Inc. | Health Care | $93.4M | 0 | 5.4% | 0 | No Change |
| RYTM | None | Rhythm Pharmaceuticals, Inc. | Healthcare | $76.9M | 0 | 4.4% | 0 | No Change |
| KYMR | None | Kymera Therapeutics, Inc. | General | $52.0M | 0 | 3.0% | 0 | No Change |
| ARGX | None | Argenx SE | Health Care | $48.9M | 0 | 2.8% | 0 | No Change |
| ASND | None | Ascendis Pharma A/S | Health Care | $45.0M | 0 | 2.6% | 0 | +100.0% |
| XEN.TO | None | Xenon Pharmaceuticals Inc. | General | $41.3M | 0 | 2.4% | 0 | No Change |
Recent Buys (13F)
| Ticker | Amount | % Chg | Weight | Status |
|---|---|---|---|---|
| ASNDAscendis Pharma A/S | $45.0M | +100.0% | 2.6% | New |
Recent Sells (13F)
| Ticker | Amount | % Chg | Weight | Status |
|---|---|---|---|---|
| ASCBAscendis Pharma A/S | $45.0M | -100.0% | 0.0% | Sold Out |
13F Sector Breakdown
Health Care48.8%
General33.9%
Healthcare17.3%
| Sector | Stocks | Value | Exposure |
|---|---|---|---|
| Health Care | 19 | $845.9M | 48.8% |
| General | 25 | $588.3M | 33.9% |
| Healthcare | 3 | $299.9M | 17.3% |